<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261962</url>
  </required_header>
  <id_info>
    <org_study_id>FAPESP:2010/08787-1</org_study_id>
    <nct_id>NCT01261962</nct_id>
  </id_info>
  <brief_title>Modulation of Immune Response by Oral Zinc Supplementation in Chemotherapy for Colon Cancer</brief_title>
  <official_title>Modulation of Immune Response by Oral Zinc Supplementation in Adjuvant Chemotherapy for Colon Cancer: a Study of Global Gene Expression and Function of Humoral Immunity and Neutrophils</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In leukocytes of patients undergoing adjuvant chemotherapy for colon cancer treatment:
      a)identify genes modulated by oral supplementation of zinc; b) evaluate the effects of oral
      zinc supplementation on humoral immunity and neutrophil function. The study will be conducted
      on 30 adult patients aged grater than 18 years, of both genders who have undergone surgical
      resection of colonic neoplastic lesions without metastatic lesion. Patients will be
      randomized into two groups, with the first (Group QT Zn, n = 15) receive 70 mg/d of zinc for
      16 weeks and the second will receive placebo (QT Placebo Group, n = 15). The study will also
      include 30 healthy volunteers who receive supplementation of 70 mg/d of Zn (C Zn group, n =
      15) or placebo (Group C Placebo, n = 15). Zinc supplementation or placebo for all study
      groups will start two days before the volunteers received the pneumococcal vaccine,
      polyvalent 23. Fifteen days after vaccination, patients begin chemotherapy as pre-established
      criteria by the Oncology Service. Will be monitored the parameters of nutritional status
      (anthropometry, bioelectrical impedance, food intake, and laboratory tests) adverse effects,
      according to rules of the CTCAE. In the evaluation of humoral immunity, antibodies
      opsonization and in the pneumococcal polysaccharide will be measured. Will be evaluated the
      function of neutrophils by measuring DNA NETs and quantified calprotectin and elastase
      released in the culture supernatants of activated neutrophils. RT-qPCR will be done of genes
      differentially expressed(DEGS) on activated leukocytes. In six volunteers from each group
      will be analyzed global gene expression from RNA extracted from leukocytes by microarray;
      will be detected and correlated the molecular pathways modulated by zinc by MetaCore software
      (GeneGo). The DEGS will be validated by RT-qPCR.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression</measure>
    <time_frame>18 months</time_frame>
    <description>Modulation of genes related to immune response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Humoral immunity and neutrophil function</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Adjuvant Chemotherapy</condition>
  <condition>Colon Cancer</condition>
  <condition>Immunity</condition>
  <arm_group>
    <arm_group_label>Chemotherapy and zinc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in adjuvant chemotherapy supplemented with zinc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in adjuvant chemotherapy with placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control and zinc</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy patients supplemented with zinc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers received placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>zinc</intervention_name>
    <description>zinc sulfate, 35 mg twice daily for 4 months</description>
    <arm_group_label>Chemotherapy and zinc</arm_group_label>
    <arm_group_label>Control and zinc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, One capsule, twice daily for 4 months</description>
    <arm_group_label>Chemotherapy placebo</arm_group_label>
    <arm_group_label>Control Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 18 years

          -  Diagnostic histopathology of colon cancer stage III (Dukes' stage C)

          -  Performance Scale Karnofsky greater or equal to 70%

          -  Have been subjected to resection of the primary neoplastic lesion in more than 8 weeks
             before start of chemotherapy

          -  Patient in the first cycle of chemotherapy in adjuvant XELOX regimen.

        Exclusion Criteria:

          -  Patients with a history of autoimmune or inflammatory disease, active infectious
             disease, liver disease, renal failure or diabetes mellitus

          -  Patients with metastatic disease

          -  Have previously received radiotherapy or chemotherapy

          -  Use of GCSF-Granulokine ® (growth-stimulating factor granulocyte)

          -  Use of immunosuppressive drugs, diuretics and supplements of zinc or copper.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selma Freire C. Cunha, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sao Paulo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Camila Bitu M. Braga, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sao Paulo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Camila Bitu M. Braga, Msc</last_name>
    <phone>55-16-36023369</phone>
    <email>camilabitu@usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Selma Freire C. Cunha, PhD</last_name>
    <phone>55-16-36013369</phone>
    <email>sfreire@fmrp.usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Departament of Clinical Oncology, Sao Paulo University</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>Sao Paulo</state>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camila Bitu M. Braga, Msc</last_name>
      <phone>55-16-36023369</phone>
      <email>camilabitu@usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Selma Freire C. Cunha, PhD</last_name>
      <phone>55-16-36023369</phone>
      <email>sfreire@fmrp.usp.br</email>
    </contact_backup>
    <investigator>
      <last_name>Fernanda Maris Peria, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camila Bitu M. Braga, Msc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2010</study_first_submitted>
  <study_first_submitted_qc>December 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2010</study_first_posted>
  <last_update_submitted>December 16, 2010</last_update_submitted>
  <last_update_submitted_qc>December 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Selma Freire de Carvalho da Cunha</name_title>
    <organization>University of Sao Paulo</organization>
  </responsible_party>
  <keyword>Humoral immunity</keyword>
  <keyword>Neutrophil function</keyword>
  <keyword>Gene expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

